Literature DB >> 7688204

Topical treatment of ichthyoses and Darier's disease with 13-cis-retinoic acid. A clinical and immunohistochemical study.

P M Steijlen1, D O Reifenschweiler, F C Ramaekers, G N van Muijen, R Happle, M Link, D J Ruiter, P C van de Kerkhof.   

Abstract

In a bilaterally paired double-blind comparison study, a cream containing 0.1% 13-cis-retinoic acid (13-cis-RA) and cream base only were applied over 4 weeks in seven patients with non-erythrodermic lamellar ichthyosis (NELI), two patients with Darier's disease and one patient with autosomal dominant ichthyosis vulgaris (ADIV). In two patients with NELI and two patients with Darier's disease a half-side effect was observed in favour of the side treated with 13-cis-RA. In three patients an induction of cytokeratin-4, and in one of these patients expression of cytokeratin-13, were observed after therapy. Topical 13-cis-RA appears to be a promising approach in the treatment of disorders of keratinization. The selective modulation of the cytokeratin pattern may provide an immunohistochemical tool to investigate the mode of action of retinoids.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688204     DOI: 10.1007/bf00372013

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  27 in total

1.  Differentiation-related changes of cytokeratin expression in cultured keratinocytes and in fetal, newborn, and adult epidermis.

Authors:  G N Van Muijen; S O Warnaar; M Ponec
Journal:  Exp Cell Res       Date:  1987-08       Impact factor: 3.905

2.  Distribution of cytokeratin polypeptides in epithelia of the adult human urinary tract.

Authors:  H E Schaafsma; F C Ramaekers; G N van Muijen; E C Ooms; D J Ruiter
Journal:  Histochemistry       Date:  1989

Review 3.  The retinoids. A review of their clinical pharmacology and therapeutic use.

Authors:  C E Orfanos; R Ehlert; H Gollnick
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

4.  Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression.

Authors:  H E Schaafsma; F C Ramaekers; G N van Muijen; E B Lane; I M Leigh; H Robben; A Huijsmans; E C Ooms; D J Ruiter
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

5.  Topical treatment with 13-cis-retinoic acid improves Darier's disease and induces the expression of a unique keratin pattern.

Authors:  P M Steijlen; R Happle; G N van Muijen; P C van de Kerkhof
Journal:  Dermatologica       Date:  1991

6.  Diazacholesterol-induced ichthyosis in the hairless mouse. Assay for comparative potency of topical retinoids.

Authors:  J C Chung; M Y Law; S T Elliott; P M Elias
Journal:  Arch Dermatol       Date:  1984-03

7.  Monoclonal antibody to keratin filaments, specific for glandular epithelia and their tumors. Use in surgical pathology.

Authors:  F Ramaekers; A Huysmans; O Moesker; A Kant; P Jap; C Herman; P Vooijs
Journal:  Lab Invest       Date:  1983-09       Impact factor: 5.662

8.  Tissue distribution of keratin 7 as monitored by a monoclonal antibody.

Authors:  F Ramaekers; A Huysmans; G Schaart; O Moesker; P Vooijs
Journal:  Exp Cell Res       Date:  1987-05       Impact factor: 3.905

9.  Percutaneous absorption of retinoids: influence of vehicle, light exposure, and dose.

Authors:  P A Lehman; J T Slattery; T J Franz
Journal:  J Invest Dermatol       Date:  1988-07       Impact factor: 8.551

10.  [Topical treatment of normal and pathological human skin with vitamin A acid (tretinoin)].

Authors:  G Plewig; H H Wolff; O Braun-Falco
Journal:  Arch Klin Exp Dermatol       Date:  1971
View more
  5 in total

1.  Regulation of keratin expression by retinoids.

Authors:  Hans Törmä
Journal:  Dermatoendocrinol       Date:  2011-07-01

Review 2.  Management of Darier disease: A review of the literature and update.

Authors:  Roger N Haber; Nicole G Dib
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

3.  Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

Authors:  J G S Veit; Y Poumay; D Mendes; J Kreitinger; L Walker; A Paquet; C Menigot; F Zolezzi; A S Paller; P Diaz
Journal:  Skin Health Dis       Date:  2021-03-26

Review 4.  Characterization of CYP26B1-Selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.

Authors:  Joachim G S Veit; Valérie De Glas; Benoît Balau; Haoming Liu; Florence Bourlond; Amy S Paller; Yves Poumay; Philippe Diaz
Journal:  J Invest Dermatol       Date:  2020-06-04       Impact factor: 8.551

Review 5.  Therapeutic Options for the Treatment of Darier's Disease: A Comprehensive Review of the Literature.

Authors:  Nardin Hanna; Megan Lam; Patrick Fleming; Charles W Lynde
Journal:  J Cutan Med Surg       Date:  2021-11-28       Impact factor: 2.854

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.